M
Meng Fen Wu
Researcher at Baylor College of Medicine
Publications - 22
Citations - 5529
Meng Fen Wu is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Antigen & Immunotherapy. The author has an hindex of 20, co-authored 22 publications receiving 4286 citations. Previous affiliations of Meng Fen Wu include Center for Cell and Gene Therapy & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
Chrystal U. Louis,Chrystal U. Louis,Barbara Savoldo,Barbara Savoldo,Gianpietro Dotti,Gianpietro Dotti,Martin Pule,Eric Yvon,G. Doug Myers,Claudia Rossig,Heidi V. Russell,Oumar Diouf,Oumar Diouf,Enli Liu,Hao Liu,Meng Fen Wu,Adrian P. Gee,Zhuyong Mei,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner +23 more
TL;DR: It is shown that GD2-CAR T cells can induce complete tumor responses in patients with active neuroblastoma; these CAR T cells may have extended, low-level persistence in patients, and such persistence was associated with longer survival.
Journal ArticleDOI
Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed,Vita S. Brawley,Meenakshi Hegde,Catherine Robertson,Alexia Ghazi,Claudia Gerken,Enli Liu,Olga Dakhova,Aidin Ashoori,Amanda Corder,Tara Gray,Meng Fen Wu,Hao Liu,John Hicks,Nino Rainusso,Gianpietro Dotti,Zhuyong Mei,Bambi Grilley,Adrian P. Gee,Cliona M. Rooney,Malcolm K. Brenner,Helen E. Heslop,Winfried S. Wels,Lisa L. Wang,Peter M. Anderson,Stephen Gottschalk +25 more
TL;DR: This first evaluation of the safety and efficacy of HER2-CAR T cells in patients with cancer shows the cells can persist for 6 weeks without evident toxicities, setting the stage for studies that combine Her2- CAR T cells with other immunomodulatory approaches to enhance their expansion and persistence.
Journal ArticleDOI
HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
Nabil Ahmed,Nabil Ahmed,Vita S. Brawley,Vita S. Brawley,Meenakshi Hegde,Meenakshi Hegde,Kevin Bielamowicz,Mamta Kalra,Daniel Landi,Daniel Landi,Catherine Robertson,Tara Gray,Oumar Diouf,Amanda Wakefield,Amanda Wakefield,Alexia Ghazi,Claudia Gerken,Claudia Gerken,Zhongzhen Yi,Zhongzhen Yi,Aidin Ashoori,Meng Fen Wu,Hao Liu,Cliona M. Rooney,Gianpietro Dotti,Adrian P. Gee,Adrian P. Gee,Jack Su,Yvonne Kew,David S. Baskin,Yi Jonathan Zhang,Pamela New,Bambi Grilley,Bambi Grilley,Milica Stojakovic,Milica Stojakovic,John Hicks,Suzanne Zein-Eldin Powell,Malcolm K. Brenner,Helen E. Heslop,Robert G. Grossman,Winfried S. Wels,Stephen Gottschalk +42 more
TL;DR: Investigation of whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)–modified virus-specific T cells (VSTs) is safe and whether these cells have antiglioblastoma activity found them to be well tolerated.
Journal ArticleDOI
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
Catherine M. Bollard,Catherine M. Bollard,Stephen Gottschalk,Stephen Gottschalk,Vicky Torrano,Vicky Torrano,Oumar Diouf,Oumar Diouf,Stephanie Ku,Stephanie Ku,Yasmin Hazrat,Yasmin Hazrat,George Carrum,George Carrum,Carlos A. Ramos,Carlos A. Ramos,Luis Fayad,Elizabeth J. Shpall,Barbara Pro,Hao Liu,Hao Liu,Meng Fen Wu,Meng Fen Wu,Daniel Lee,Daniel Lee,Andrea M. Sheehan,Andrea M. Sheehan,Youli Zu,Youli Zu,Adrian P. Gee,Adrian P. Gee,Malcolm K. Brenner,Malcolm K. Brenner,Helen E. Heslop,Helen E. Heslop,Cliona M. Rooney,Cliona M. Rooney +36 more
TL;DR: Autologous T cells directed to the L MP2 or LMP1 and LMP2 antigens can induce durable complete responses without significant toxicity and earlier use in the disease course may reduce delayed treatment-related mortality.
Journal ArticleDOI
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
Meenakshi Hegde,Amanda Corder,Kevin Chow,Malini Mukherjee,Aidin Ashoori,Yvonne Kew,Yi Jonathan Zhang,David S. Baskin,Fatima A. Merchant,Vita S. Brawley,Tiara T. Byrd,Simone Krebs,Meng Fen Wu,Hao Liu,Helen E. Heslop,Stephen Gottachalk,Eric Yvon,Nabil Ahmed +17 more
TL;DR: Both HER2/IL-13Rα2-bispecific T cell products offset antigen escape, producing enhanced effector activity in vitro immunoassays and in an orthotopic xenogeneic murine model.